Semaglutide Linked to Fewer Asthma Attacks and COPD Flare-Ups

Real-World Health Records Show Fewer Respiratory Flare-Ups

Semaglutide is associated with a 20 percent reduction in chronic obstructive pulmonary disease (COPD) flare-ups and a nearly 40 percent reduction in asthma attacks. Researchers presented these observational findings at the European Respiratory Society (ERS) Congress in Barcelona, Spain. The project analyzed United Kingdom (UK) electronic health records to assess acute respiratory events in adults with airway disease.

The research team was led by Chloe Bloom, a clinical associate professor in respiratory epidemiology at the National Heart and Lung Institute at Imperial College London. Dr. Bohee Lee presented the data on site. The team conducted four parallel observational studies that tracked between 20,000 and 22,000 people who started glucagon-like peptide-1 (GLP-1) receptor agonists or an older class of diabetes drugs called sulfonylureas.

How Semaglutide Compares with Other Diabetes Medications

Patients prescribed GLP-1 receptor agonists experienced fewer acute airway episodes than similar patients prescribed sulfonylureas. The difference in respiratory events was most pronounced among patients taking semaglutide. For individuals with asthma, semaglutide use corresponded to a nearly 40 percent drop in attacks compared to the sulfonylurea comparison group.

Patients with COPD who took semaglutide experienced a 20 percent reduction in disease flare-ups. Previous laboratory and clinical work indicates that GLP-1 receptor agonists possess anti-inflammatory properties that could influence lung tissue. However, standard clinical trials for diabetes and obesity treatments have not tracked asthma or COPD attacks as formal study endpoints.

Observational Evidence and the Need for Clinical Trials

This project evaluated retrospective medical records rather than testing patients in a randomized controlled trial. Because the dataset reflects real-world clinical entries, unmeasured differences between patient groups could influence the observed rates of respiratory attacks. Dedicated trials that randomize patients are required to verify whether semaglutide directly causes these respiratory improvements.

Dr. Alexander Mathioudakis, chair of the European Respiratory Society Group on Airway Pharmacology and Treatment and senior lecturer at the University of Manchester, stated that metabolic dysfunction and obesity frequently occur alongside chronic airway disease. Mathioudakis noted that future metabolic trials should record asthma attacks, COPD exacerbations, lung function tests, and symptom scores to evaluate systemic airway management.

What the Findings Mean for Current Prescribing Guidance

Patients should not start semaglutide specifically to treat asthma or COPD. Bloom stated that while these associations are encouraging, individuals should only use GLP-1 receptor agonists within authorized indications for type 2 diabetes or weight management. Prescribers cannot alter respiratory therapy based on retrospective observational data alone.

People already taking semaglutide for type 2 diabetes or obesity who also have chronic airway conditions might receive secondary respiratory benefits. Anyone managing asthma or COPD alongside metabolic conditions should speak with their primary care clinician or pulmonologist before making any changes to their existing inhaler regimens or metabolic prescriptions.

• Semaglutide reduced asthma attacks by up to 40 percent in UK health records.
• COPD exacerbations dropped by 20 percent compared to sulfonylurea treatment.
• The findings represent observational data and require verification in randomized clinical trials.
• Current prescribing guidelines remain limited to type 2 diabetes and obesity management.